Africa’s EVA Pharma, France’s DNA Script, and Belgium’s Quantoom Biosciences have signed a Memorandum of Understanding which aims to develop the first-ever digital-to-biologics, end-to-end mRNA production platform, focusing on nucleic acid-based vaccines and therapeutics, including mRNA and saRNA vaccines for both human and animal health.

The platform will integrate DNA Script’s enzymatic DNA synthesis technologies with Quantoom’s Ntensify mRNA synthesis and Ncapsulate formulation technologies, plus EVA Pharma’s vaccine development, GMP sterile manufacturing expertise and commercialization capabilities. 

The collaboration aims to address market needs, including rapid responses to infectious disease outbreaks and routine immunizations. The shared vision is to produce 100 million doses of RNA-based vaccines annually, fostering localization and strengthening regional autonomy in biopharmaceutical manufacturing. This collaboration will focus on developing next-generation, saRNA-based vaccines, targeting both human and animal health.

This initiative will contribute to achieving Africa CDC’s target of 60% local vaccine production by 2040 and Egypt’s ambitious goal to manufacture 385 million vaccine doses annually by 2030.

“This moment will reshape African and global health security as we know it,” said Dr. Riad Armanious, CEO of EVA Pharma. “Our cross-continental collaboration will empower patients with next-generation, scalable, and versatile solutions that transform what once took years into a process achievable in weeks.”

Marc Montserrat, CEO of DNA Script, said, “Our collaboration with EVA Pharma and Univercells-Quantoom to implement our proprietary enzymatic DNA synthesis technology directly supports the mission to accelerate vaccine development and delivery worldwide, and more broadly aligns with our vision to make biology programmable. By dramatically reducing the time needed to produce DNA templates, and by enabling the synthesis of longer and more complex DNA sequences, we’re helping ensure that innovative vaccine technology can reach those at highest risk during emerging epidemics more rapidly than ever before.”

José Castillo, CEO of Quantoom Biosciences, added: “This collaboration showcases the transformative power of combining complementary expertise across borders. Together, we are not only advancing RNA technologies but also addressing global health inequities by making life-saving vaccines and therapeutics accessible to underserved populations.”